Correction to: Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials (Cardiovasc Drugs Ther, 10.1007/s10557-018-6784-z)

Harold E. Bays; Robert S. Rosenson; Marie T. Baccara-Dinet; Michael J. Louie; Desmond Thompson; G. Kees Hovingh

doi:https://doi.org/10.1007/s10557-018-6792-z

Correction to: Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials (Cardiovasc Drugs Ther, 10.1007/s10557-018-6784-z)

Harold E. Bays, Robert S. Rosenson, Marie T. Baccara-Dinet, Michael J. Louie, Desmond Thompson, G. Kees Hovingh

Research output: Contribution to journal › Erratum/Corrigendum › Academic

1 Citation (Scopus)

Abstract

The original version of this article unfortunately contained a mistake in the Discussion section. The line that currently reads "During this 4-week period while off PCSK9 monoclonal antibody therapy, the medical staff should ensure an accurate 4-week pill count of concurrently administered statin and/ or other lipid-altering drugs." should be changed to "During this 4-week stabilization period (while off PCSK9 monoclonal antibody therapy for at least 8 weeks), the medical staff should ensure an accurate 4-week pill count of concurrently administered statin and/or other lipid-altering drugs.".

Original language	English
Pages (from-to)	181
Journal	Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy
Volume	32
Issue number	2
DOIs	https://doi.org/10.1007/s10557-018-6792-z
Publication status	Published - 2018

Access to Document

https://doi.org/10.1007/s10557-018-6792-z

Cite this

Bays, H. E., Rosenson, R. S., Baccara-Dinet, M. T., Louie, M. J., Thompson, D., & Kees Hovingh, G. (2018). Correction to: Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials (Cardiovasc Drugs Ther, 10.1007/s10557-018-6784-z). Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy, 32(2), 181. https://doi.org/10.1007/s10557-018-6792-z

Bays, Harold E. ; Rosenson, Robert S. ; Baccara-Dinet, Marie T. et al. / Correction to: Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials (Cardiovasc Drugs Ther, 10.1007/s10557-018-6784-z). In: Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy. 2018 ; Vol. 32, No. 2. pp. 181.

@article{bde3c3ce46664eb2abcc0d2140a1defe,

title = "Correction to: Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials (Cardiovasc Drugs Ther, 10.1007/s10557-018-6784-z)",

abstract = "The original version of this article unfortunately contained a mistake in the Discussion section. The line that currently reads {"}During this 4-week period while off PCSK9 monoclonal antibody therapy, the medical staff should ensure an accurate 4-week pill count of concurrently administered statin and/ or other lipid-altering drugs.{"} should be changed to {"}During this 4-week stabilization period (while off PCSK9 monoclonal antibody therapy for at least 8 weeks), the medical staff should ensure an accurate 4-week pill count of concurrently administered statin and/or other lipid-altering drugs.{"}.",

author = "Bays, {Harold E.} and Rosenson, {Robert S.} and Baccara-Dinet, {Marie T.} and Louie, {Michael J.} and Desmond Thompson and {Kees Hovingh}, G.",

year = "2018",

doi = "https://doi.org/10.1007/s10557-018-6792-z",

language = "English",

volume = "32",

pages = "181",

journal = "Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy",

issn = "0920-3206",

publisher = "Kluwer Academic Publishers",

number = "2",

}

Bays, HE, Rosenson, RS, Baccara-Dinet, MT, Louie, MJ, Thompson, D & Kees Hovingh, G 2018, 'Correction to: Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials (Cardiovasc Drugs Ther, 10.1007/s10557-018-6784-z)', Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy, vol. 32, no. 2, pp. 181. https://doi.org/10.1007/s10557-018-6792-z

Correction to: Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials (Cardiovasc Drugs Ther, 10.1007/s10557-018-6784-z). / Bays, Harold E.; Rosenson, Robert S.; Baccara-Dinet, Marie T. et al.
In: Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy, Vol. 32, No. 2, 2018, p. 181.

Research output: Contribution to journal › Erratum/Corrigendum › Academic

TY - JOUR

T1 - Correction to: Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials (Cardiovasc Drugs Ther, 10.1007/s10557-018-6784-z)

AU - Bays, Harold E.

AU - Rosenson, Robert S.

AU - Baccara-Dinet, Marie T.

AU - Louie, Michael J.

AU - Thompson, Desmond

AU - Kees Hovingh, G.

PY - 2018

Y1 - 2018

N2 - The original version of this article unfortunately contained a mistake in the Discussion section. The line that currently reads "During this 4-week period while off PCSK9 monoclonal antibody therapy, the medical staff should ensure an accurate 4-week pill count of concurrently administered statin and/ or other lipid-altering drugs." should be changed to "During this 4-week stabilization period (while off PCSK9 monoclonal antibody therapy for at least 8 weeks), the medical staff should ensure an accurate 4-week pill count of concurrently administered statin and/or other lipid-altering drugs.".

AB - The original version of this article unfortunately contained a mistake in the Discussion section. The line that currently reads "During this 4-week period while off PCSK9 monoclonal antibody therapy, the medical staff should ensure an accurate 4-week pill count of concurrently administered statin and/ or other lipid-altering drugs." should be changed to "During this 4-week stabilization period (while off PCSK9 monoclonal antibody therapy for at least 8 weeks), the medical staff should ensure an accurate 4-week pill count of concurrently administered statin and/or other lipid-altering drugs.".

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85047541607&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/29713852

U2 - https://doi.org/10.1007/s10557-018-6792-z

DO - https://doi.org/10.1007/s10557-018-6792-z

M3 - Erratum/Corrigendum

C2 - 29713852

SN - 0920-3206

VL - 32

SP - 181

JO - Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy

JF - Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy

IS - 2

ER -

Bays HE, Rosenson RS, Baccara-Dinet MT, Louie MJ, Thompson D, Kees Hovingh G. Correction to: Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials (Cardiovasc Drugs Ther, 10.1007/s10557-018-6784-z). Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy. 2018;32(2):181. doi: https://doi.org/10.1007/s10557-018-6792-z

Correction to: Assessment of the 1% of Patients with Consistent < 15% Reduction in Low-Density Lipoprotein Cholesterol: Pooled Analysis of 10 Phase 3 ODYSSEY Alirocumab Trials (Cardiovasc Drugs Ther, 10.1007/s10557-018-6784-z)

Abstract

Access to Document

Other files and links

Cite this